The significance of interferon-γ in HIV-1 pathogenesis, therapy, and prophylaxis

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Roff, Shannon R ^a   Noon Song, Ezra N ^a   Yamamoto, Janet K ^a  

^a University of Florida   (United States)

Author keywords

Anti retroviral therapy; HIV 1 pathogenesis; HIV 1 vaccine; IFN therapy; Interferon

Indexed keywords

EPITOPE; GAMMA INTERFERON; INTERLEUKIN 7; PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE TRANSMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PROPHYLAXIS; PROTEIN EXPRESSION; REVIEW; VACCINATION; VIRUS LOAD; ANTIVIRAL ACTIVITY; CD8+ T LYMPHOCYTE; DISEASE ASSOCIATION; IMMUNOREGULATION; MOTHER CHILD RELATION; NATURAL KILLER CELL; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE;

EID: 84987788935     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. Spellberg B, Edwards JE Jr. Type 1/type 2 immunity in infectious diseases. Clin Infect Dis (2001) 32(1):76-102. doi: 10.1086/317537.
2. Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, Koyasu S. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol (2001) 22(10):556-60. doi:10.1016/S1471-4906(01)02005-1.
3. Harris DP, Goodrich S, Gerth AJ, Peng SL, Lund FE. Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J Immunol (2005) 174(11):6781-90.
4. Koirala J, Adamski A, Koch L, Stueber D, El-Azizi M, Khardori NM, et al. Interferon-gamma receptors in HIV-1 infection. AIDS Res Hum Retroviruses (2008) 24(8):1097-102. doi:10.1089/aid.2007.0261.
5. Cobos Jiménez V, Booiman T, de Taeye SW, van Dort KA, Rits MA, Hamann J, et al. Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons. Sci Rep (2012) 2:763. doi:10.1038/srep00763.
6. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 15:749-95. doi:10.1146/annurev.immunol.15.1.749.
7. Kumar SB, Rice CE, Milner DA Jr, Ramirez NC, Ackerman WE IV, Mwapasa V, et al. Elevated cytokine and chemokine levels in the placenta are associated with in-utero HIV-1 mother-to-child transmission. AIDS (2012) 26:685-94. doi:10.1097/QAD.0b013e3283519b00.
8. John-Stewart GC, Mbori-Ngacha D, Payne BL, Farquhar C, Richardson BA, Emery S, et al. HIV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission. J Infect Dis (2009) 199:889-98. doi:10.1086/597120.
9. Lohman-Payne B, Slyker JA, Moore S, Maleche-Obimbo E, Wamalwa DC, Richardson BA, et al. Breast milk cellular HIV-specific interferon gamma responses are associated with peripartum HIV transmission. AIDS (2012) 26:2007-16. doi:10.1097/QAD.0b013e328359b7e0.
10. Lohman BL, Slyker JA, Richardson BA, Farquhar C, Mabuka JM, Crudder C, et al. Longitudinal assessment of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants. J Virol (2005) 79(13):8121-30. doi:10.1128/JVI.79.13.8121-8130.2005.
11. Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, Miyamoto M, et al. Strong HIV-1 specific T cell responses in HIV-1 exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS One (2006) 20(1):e102. doi:10.1371/journal.pone.0000102.
12. Kaul R, Rowland-Jones SL, Kimani J, Dong R, Yang H-B, Kiama P, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest (2001) 107(3):341-9. doi:10.1172/JCI10714.
13. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delated responses in acute hepatitis B and C virus infections. J Virol (2009) 83:3719-33. doi:10.1128/JVI.01844-08.
14. Cao J, McNevin J, Holte S, Fink L, Corey L, McElrath MJ. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T-cells in primary HIV-1 infection. J Virol (2003) 77:6867-78. doi:10.1128/JVI.77.12.6867-6878.2003.
15. Dalod M, Dupuis M, Deschemin JC, Goujard C, Deveau C, Meyer L, et al. Weak anti-HIV CD8+ T-cell effector activity in HIV primary infection. J Clin Invest (1999) 104:1431-9. doi:10.1172/JCI7162.
16. Lieberman J. Tracking the killers: how should we measure CD8 T cells in HIV infection? AIDS (2004) 18:1489-93. doi:10.1097/01.aids.0000131320.75396.4d.
17. Zanussi S, D'Andrea MD, Simonelli C, Tirelli U, DePaoli P. Serum levels of RANTES and MIP-1α in HIV-positive long-term survivors and progressor patients. AIDS (1996) 10:1431-2. doi:10.1097/00002030-199610000-00018.
18. Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol (1996) 156:2616-23.
19. Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, et al. High levels of anti-human immunodeficiency virus type-1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J Virol (1995) 69:5838-42.
20. Watanabe D, Uehira T, Yonemoto H, Bando H, Ogawa Y, Yajima K, et al. Sustained high levels of serum interferon-gamma during HIV-1 infection: a specific trend different from other cytokines. Viral Immunol (2010) 23(6):619-25. doi:10.1089/vim.2010.0065.
21. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, et al. Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis (2012) 206(7):993-1001. doi:10.1093/infdis/jis465.
22. Lieberman J, Shankar P, Manjunath N, Andersson J. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood (2001) 98:1667-77. doi:10.1182/blood.V98.6.1667.
23. Roberts L, Passmore JA, Williamson C, Little F, Bebell LM, Mlisana K, et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS (2010) 24:819-31. doi:10.1097/QAD.0b013e3283367836.
24. Isaacs A, Lindermann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci (1957) 147:258-67. doi:10.1098/rspb.1957.0048.
25. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev (2001) 14(4):778-809. doi:10.1128/CMR.14.4.778-809.2001.
26. Schroeder J, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol (2004) 75:163-89. doi:10.1189/jlb.0603252.
27. Polyak MJ, Vivithanaporn P, Maingat FG, Walsh JG, Branton W, Cohen EA, et al. Differential type 1 interferon-regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence. FASEB J (2013) 27(7):2829-44. doi:10.1096/fj.13-227868.
28. Tokarev A, Skasko M, Fitzpatrick K, Guatelli J. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res Hum Retroviruses (2009) 25(12):1197-210. doi:10.1089/aid.2009.0253.
29. Simm M. The innate cellular responses to HIV-1 invasion: emerging molecules of ancient-defense mechanisms. Arch Immunol Ther Exp (Warsz) (2007) 55(3):131-8. doi:10.1007/s00005-007-0023-9.
30. Bitzegeio J, Sampias M, Bieniasz PD, Hatziioannou T. Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses. J Virol (2013) 87(6):3549-60. doi:10.1128/JVI.03219-12.
31. Yamamoto JK, Barré-Sinoussi F, Bolton V, Pedersen NC, Gardner MB. Human alpha-and beta-interferon but not gamma-suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res (1986) 6(2):143-52. doi:10.1089/jir.1986.6.143.
32. Kirchner H. The interferon system as an integral part of the defense system against infections. Antiviral Res (1986) 6(1):1-17. doi:10.1016/0166-3542(86)90035-5.
33. Mackewicz CE, Ortega H, Levy JA. Effect of cytokines on HIV replication in CD4+ lymphocytes: lack of identity with the CD8+ cell antiviral factor. Cell Immunol (1994) 153(2):329-43. doi:10.1006/cimm.1994.1032.
34. Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS (1991) 5(12):1405-17. doi:10.1097/00002030-199112000-00001.
35. Levy JA, editor. Effect of HIV on various tissues and organ systems in the host. 3rd ed. Chap. 5. HIV and the Pathogenesis of AIDS. Washington DC: ASM Press (2007). p. 165-207.
36. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 68(9):6103-10.
37. Yang OO, Daar ES, Ng HL, Shih R, Jamieson BD. Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res Hum Retroviruses (2011) 27(4):391-8. doi:10.1089/aid.2010.0183.
38. Leeansyah E, Malone DF, Anthony DD, Sandberg JK. Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS (2013) 8(2):117-24. doi:10.1097/COH.0b013e32835c7134.
39. Katsikis PD, Mueller YM, Villinger F. The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point? PLoS Pathog (2011) 7(8):e1002055. doi:10.1371/journal.ppat.1002055.
40. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med (2001) 344(10):720-5. doi:10.1056/NEJM200103083441003.
41. Lavreys L, Baeten JM, Chohan V, McClelland RS, Hassan WM, Richardson BA, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis (2006) 42(9):1333-9. doi:10.1086/503258.
42. Gromo G, Geller RL, Inverardi L, Bach FH. Signal requirements in the step-wise functional maturation of cytotoxic T lymphocytes. Nature (1987) 327(6121):424-6. doi:10.1038/327424a0.
43. Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol (1989) 143(4):1210-4.
44. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med (2012) 4(123):123ra25. doi:10.1126/scitranslmed.3003165.
45. Betts MR, Krowka JF, Kepler TB, Davidian M, Christopherson C, Kwok S, et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res Hum Retroviruses (1999) 15(13):1219-28. doi:10.1089/088922299310313.
46. Blankson JN. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res (2010) 85(1):295-302. doi:10.1016/j.antiviral.2009.08.007.
47. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity (2007) 27(3):406-16. doi:10.1016/j.immuni.2007.08.010.
48. McNicholl JM, Promadej N. Insights into the role of host genetic and T-cell factors in resistance to HIV transmission from studies of highly HIV-exposed Thais. Immunol Res (2004) 29(1-3):161-74. doi:10.1385/IR:29:1-3:161.
49. Agosti JM, Coombs RW, Collier AC, Paradise MA, Benedetti JK, Jaffe HS, et al. A randomized, double-blind, phase I/II trial of tumor necrosis factor and interferon-gamma for treatment of AIDS-related complex (Protocol 025 from the AIDS Clinical Trials Group). AIDS Res Hum Retroviruses (1992) 8(5):581-7. doi:10.1089/aid.1992.8.581.
50. Kaplan LD, Abrams DI, Sherwin SA, Kahn J, Volberding PA. A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex. Biotechnol Ther (1989-1990) 1(3):229-36.
51. Lane HC, Davey RT Jr, Sherwin SA, Masur H, Rook AH, Manischewitz JF, et al. A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). J Clin Immunol (1989) 9(4):351-61. doi:10.1007/BF00918667.
52. Heagy W, Groopman J, Schindler J, Finberg R. Use of IFN-gamma in patients with AIDS. J Acquir Immune Defic Syndr (1990) 3(6):584-90.
53. Krown SE. Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma. J Interferon Cytokine Res (1998) 18(4):209-14. doi:10.1089/jir.1998.18.209.
54. Krown SE. Interferon and other biologic agents for the treatment of Kaposi's sarcoma. Hematol Oncol Clin North Am (1991) 5(2):311-22.
55. Shearer WT, Kline MW, Abramson SL, Fenton T, Starr SE, Douglas SD. Recombinant human gamma interferon in human immunodeficiency virus-infected children: safety, CD4(+)-lymphocyte count, viral load, and neutrophil function (AIDS Clinical Trials Group Protocol 211). Clin Diagn Lab Immunol (1999) 6(3):311-5.
56. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev (1997)1997-1998:187-228.
57. Poli G, Biswas P, Fauci AS. Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antiviral Res (1994) 24(2-3):221-33. doi:10.1016/0166-3542(94)90069-8.
58. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, et al. AIDS Clinical Trials Group A5192 Team. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1 monoinfected participants: a phase II clinical trial. J Infect Dis (2010) 201(11):1686-96. doi:10.1086/652420.
59. Aldenhoven M, Barlo NP, Sanders CJ. Therapeutic strategies for epidemic Kaposi's sarcoma. Int J STD AIDS (2006) 17(9):571-8. doi:10.1258/095646206778113131.
60. Aversa SM, Cattelan AM, Salvagno L, Crivellari G, Banna G, Trevenzoli M, et al. Treatments of AIDS-related Kaposi's sarcoma. Crit Rev Oncol Hematol (2005) 53(3):253-65. doi:10.1016/j.critrevonc.2004.10.009.
61. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, et al. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis (2004) 189(12):2185-91. doi:10.1086/420829.
62. Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, et al. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS (2012) 26(9):1105-13. doi:10.1097/QAD.0b013e3283536a93.
63. Gamaletsou MN, Sipsas NV, Kontoyiannis DP, Tsiakalos A, Kontos AN, Stefanou I, et al. Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-γ. Diagn Microbiol Infect Dis (2012) 74(4):409-11. doi:10.1016/j.diagmicrobio.2012.08.009.
64. Riddell LA, Pinching AJ, Hill S, Ng TT, Arbe E, Lapham GP, et al. A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses (2001) 17(9):789-97. doi:10.1089/088922201750251981.
65. Kedzierska K, Azzam R, Ellery P, Mak J, Jaworowski A, Crowe SM. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol (2003) 26(2):247-63. doi:10.1016/S1386-6532(02)00123-3.
66. Squires KE, Brown ST, Armstrong D, Murphy WF, Murray HW. Interferon-gamma treatment for Mycobacterium avium-intracellular complex bacillemia in patients with AIDS. J Infect Dis (1992) 166(3):686-7. doi:10.1093/infdis/166.3.686.
67. Murray HW. Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med (1996) 22(Suppl 4):S456-61. doi:10.1007/BF01743724.
68. Gasser O, Brander C, Wolbers M, Brown NV, Rauch A, Günthard HF, et al. Cohort Study. Expansion of interferon-γ-secreting HIV-specific T cells during successful antiretroviral therapy. HIV Med (2013) 14(4):241-6. doi:10.1111/j.1468-1293.2012.01040.x.
69. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood (2004) 103(3):966-72. doi:10.1182/blood-2003-04-1203.
70. Trabattoni D, Piconi S, Biasin M, Rizzardini G, Migliorino M, Seminari E, et al. Granule-dependent mechanisms of lysis are defective in CD8 T cells of HIV-infected, antiretroviral therapy-treated individuals. AIDS (2004) 18(6):859-69. doi:10.1097/00002030-200404090-00003.
71. Casazza JP, Betts MR, Picker LJ, Koup RA. Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol (2001) 75(14):6508-16. doi:10.1128/JVI.75.14.6508-6516.2001.
72. Orsilles MA, Pieri E, Cooke P, Caula C. IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy. APMIS (2006) 114(1):55-60. doi:10.1111/j.1600-0463.2006.apm_108.x.
73. Stylianou E, Aukrust P, Kvale D, Müller F, Frøland SS. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression-down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol (1999) 116(1):115-20.
74. Stylianou E, Bjerkeli V, Yndestad A, Heggelund L, Waehre T, Damås JK, et al. Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virological treatment failure in HIV-1-infected patients. Clin Exp Immunol (2003) 132(3):462-6. doi:10.1046/j.1365-2249.2003.02179.x.
75. Torre D, Speranza F, Martegani R, Pugliese A, Castelli F, Basilico C, et al. Circulating levels of IL-18 in adult and paediatric patients with HIV-1 infection. AIDS (2000) 14(14):2211-2. doi:10.1097/00002030-200009290-00023.
76. Iannello A, Tremblay C, Routy JP, Boulassel MR, Toma E, Ahmad A. Decreased levels of circulating IL-21 in HIV-infected AIDS patients: correlation with CD4+ T-cell counts. Viral Immunol (2008) 21(3):385-8. doi:10.1089/vim.2008.0025.
77. Iannello A, Boulassel MR, Samarani S, Debbeche O, Tremblay C, Toma E, et al. Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J Immunol (2010) 184(1):114-26. doi:10.4049/jimmunol.0901967.
78. Streeck H, Frahm N, Walker BD. The role of IFN-gamma Elispot assay in HIV vaccine research. Nat Protoc (2009) 4(4):461-9. doi:10.1038/nprot.2009.7.
79. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol (2003) 77(3):2081-92. doi:10.1128/JVI.77.3.2081-2092.2003.
80. Streeck H, Nixon DF. T cell immunity in acute HIV-1 infection. J Infect Dis (2010) 202(Suppl 2):S302-8. doi:10.1086/655652.
81. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol (2002) 169(11):6376-85.
82. Boaz MJ, Waters A, Murad S, Easterbrook PJ, D'Sousa E, van Wheeley C, et al. CD4 responses to conserved HIV-1 T helper epitopes show both negative and positive associations with virus load in chronically infected subjects. Clin Exp Immunol (2003) 134(3):454-63. doi:10.1111/j.1365-2249.2003.02307.x.
83. Richmond M, McKinnon LR, Kiazyk SA, Wachihi C, Kimani M, Kimani J, et al. Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function. J Virol (2011) 85(3):1275-86. doi:10.1128/JVI.01707-10.
84. Zanussi S, Simonelli C, D'Andrea M, Caffau C, Clerici M, Tirelli U, et al. CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin Exp Immunol (1996) 105(2):220-4.
85. Rehr M, Cahenzli J, Haas A, Price DA, Gostick E, Huber M, et al. Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol (2008) 82(7):3391-404. doi:10.1128/JVI.02383-07.
86. McQuillan GM, Kruszon-Moran D, Kottiri BJ, Kamimoto LA, Lam L, Cowart MF, et al. Prevalence of HIV in the US household population: the National Health and Nutrition Examination Surveys, 1988 to 2002. J Acquir Immune Defic Syndr (2006) 41(5):651-6. doi:10.1097/01.qai.0000194235.31078.f6.
87. World Health Organization (WHO). Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector. Progress report (2009). Available from: http://www.who.int/hiv/pub/2009progressreport/en.
88. Boyd MA, Hill AM. Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. Pharmacoeconomics (2010) 28(Suppl 1):17-34. doi:10.2165/11587420-000000000-00000.
89. Zolopa AR. The evolution of HIV treatment guidelines: current state-of-the-art of ART. Antiviral Res (2010) 85(1):241-4. doi:10.1016/j.antiviral.2009.10.018.
90. Guihot A, Tubiana R, Breton G, Marcelin AG, Samri A, Assoumou L, et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS (2010) 24(4):614-7. doi:10.1097/QAD.0b013e32833556f3.
91. Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, et al. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS (2010) 24(12):1867-76. doi:10.1097/QAD.0b013e32833adbcf.
92. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One (2012) 7(3):e34156. doi:10.1371/journal.pone.0034156.
93. Markowitz N, Lopardo G, Wentworth D, Gey D, Babiker A, Fox L, et al. Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study. PLoS One (2012) 7(10):e47506. doi:10.1371/journal.pone.0047506.
94. Sternfeld T, Nigg A, Belohradsky BH, Bogner JR. Treatment of relapsing Mycobacterium avium infection with interferon-gamma and interleukin-2 in an HIV-negative patient with low CD4 syndrome. Int J Infect Dis (2010) 14(Suppl 3):198-201. doi:10.1016/j.ijid.2009.08.004.
95. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J (2004) 23(8):769-73. doi:10.1097/01.inf.0000134314.65398.bf.
96. Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N, Nair G, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med (2012) 157(5):313-24. doi:10.7326/0003-4819-157-5-201209040-00004.
97. Corey DM, Kim HW, Salazar R, Illescas R, Villena J, Gutierrez L, et al. Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr (2007) 44(4):451-5. doi:10.1097/QAI.0b013e31802f8512.
98. Koenig SP, Rodriguez LA, Bartholomew C, Edwards A, Carmichael TE, Barrow G, et al. Long-term antiretroviral treatment outcomes in seven countries in the Caribbean. J Acquir Immune Defic Syndr (2012) 59(4):60-71. doi:10.1097/QAI.0b013e318245d3c1.
99. Armstrong WS. The immune reconstitution inflammatory syndrome: a clinical update. Curr Infect Dis Rep (2013) 15(1):39-45. doi:10.1007/s11908-012-0308-y.
100. Rasul S, Delapenha R, Farhat F, Gajjala J, Zahra SM. Graves' disease as a manifestation of immune reconstitution in HIV-infected individuals after initiation of highly active antiretroviral therapy. AIDS Res Treat (2011) 2011:743597. doi:10.1155/2011/743597.
101. Sharma SK, Soneja M. HIV & immune reconstitution inflammatory syndrome (IRIS). Indian J Med Res (2011) 134(6):866-77. doi:10.4103/0971-5916.92632.
102. Wiesner DL, Boulware DR. Cryptococcus-related immune reconstitution inflammatory syndrome (IRIS): pathogenesis and its clinical implications. Curr Fungal Infect Rep (2011) 5(4):252-61. doi:10.1007/s12281-011-0064-8.
103. Grant PM, Komarow L, Lederman MM, Pahwa S, Zolopa AR, Andersen J, et al. Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J Infect Dis (2012) 206(11):1715-23. doi:10.1093/infdis/jis604.
104. Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 205(1):63-77. doi:10.1084/jem.20071331.
105. Draenert R, Altfeld M, Brander C, Basgoz N, Corcoran C, Wurcel AG, et al. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods (2003) 275(1-2):19-29. doi:10.1016/S0022-1759(02)00541-0.
106. Baier-Bitterlich G, Fuchs D, Wachter H. Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Biochem Pharmacol (1997) 53(6):755-63. doi:10.1016/S0006-2952(96)00651-X.
107. Yang OO. Will we be able to "spot" an effective HIV-1 vaccine? Trends Immunol (2003) 24(2):67-72. doi:10.1016/S1471-4906(02)00034-0.
108. Lena P, Villinger F, Giavedoni L, Miller CJ, Rhodes G, Luciw P. Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. Vaccine (2002) 20(Suppl 4):A69-79. doi:10.1016/S0264-410X(02)00391-2.
109. Giavedoni L, Ahmad S, Jones L, Yilma T. Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J Virol (1997) 71(2):866-72.
110. Hosie MJ, Flynn JN, Rigby MA, Cannon C, Dunsford T, Mackay NA, et al. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J Virol (1998) 72(9):7310-9.
111. Gupta S, Leutenegger CM, Dean GA, Steckbeck JD, Cole KS, Sparger EE. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon. J Virol (2007) 81(2):465-73. doi:10.1128/JVI.00815-06.
112. Jones NG, DeCamp A, Gilbert P, Peterson ML, Gurwith M, Cao H. AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine (2009) 27(7):1136-40. doi:10.1016/j.vaccine.2008.11.071.
113. Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, Cole S, et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One (2011) 6:e20479. doi:10.1371/journal.pone.0020479.
114. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 188(10):5166-76. doi:10.4049/jimmunol.1102756.
115. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 361(23):2209-20. doi:10.1056/NEJMoa0908492.
116. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 366(14):1275-86. doi:10.1056/NEJMoa1113425.
117. Fuller DH, Rajakumar P, Che JW, Narendran A, Nyaundi J, Michael H, et al. Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. PLoS One (2012) 87(3):e33715. doi:10.1371/journal.pone.0033715.
118. von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, et al. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol (2007) 81(4):1972-9. doi:10.1128/JVI.01990-06.
119. Hansen SG, Ford JC, Lewis MS, Ventura AB, Colette M, Hughes CM, et al. Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine. Nature (2011) 473(7348):523-7. doi:10.1038/nature10003.
120. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz B, Scholz I, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 340(6135):1237874. doi:10.1126/science.1237874.
121. Blackman MJ, Morris AG. The effect of interferon treatment of targets on susceptibility to cytotoxic T-lymphocyte killing: augmentation of allogeneic killing and virus-specific killing relative to viral antigen expression. Immunology (1985) 56(3):451-7.
122. Mills FC, Brooker JS, Camerini-Otero RD. Sequences of human immunoglobulin switch regions: implications for recombination and transcription. Nucleic Acids Res (1990) 18(24):7305-16. doi:10.1093/nar/18.24.7305.
123. Welsh RM. Natural killer cells and interferon. Crit Rev Immunol (1984) 5(1):55-93.
124. Senik A, Stefanos S, Kolb JP, Lucero M, Falcoff E. Enhancement of mouse natural killer cell activity by type II interferon. Ann Immunol (Paris) (1980) 131c:349-61.
125. Halwani R, Boyer JD, Yassine-Diab B, Haddad EK, Robinson TM, Kumar S, et al. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol (2008) 180(12):7969-79.
126. Muthumani K, Kudchodkar S, Zhang D, Bagarazzi ML, Kim JJ, Boyer JD, et al. Issues for improving multiplasmid DNA vaccines for HIV-1. Vaccine (2002) 20(15):1999-2003. doi:10.1016/S0264-410X(02)00086-5.
127. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res (2008) 42(1-3):219-32. doi:10.1007/s12026-008-8076-3.
128. Coleman JK, Pu R, Martin M, Sato E, Yamamoto JK. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection. AIDS (2005) 19(14):1457-66. doi:10.1097/01.aids.0000183627.81922.be.
129. Coleman JK, Pu P, Martin MM, Noon-Song EN, Zwijnenberg R, Yamamoto JK. Feline immunodeficiency virus (FIV) vaccine and neutralizing antibodies against heterologous FIV subtype strains. Vaccine (2013). doi:10.1016/j.vaccine.2013.05.024.
130. Abbott JR, Pu R, Coleman JK, Yamamoto JK. Utilization of feline ELISPOT for mapping vaccine epitopes. Methods Mol Biol (2012) 792:47-63. doi:10.1007/978-1-61779-325-7_4.
131. Uhl EW, Martin M, Coleman JK, Yamamoto JK. Advances in FIV vaccine technology. Vet Immunol Immunopath (2008) 123:65-80. doi:10.1016/j.vetimm.2008.01.030.
132. Van Braeckel E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I, et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Infect Dis (2011) 52(4):522-31. doi:10.1093/cid/ciq160.
133. Mortara L, Gras-Masse H, Rommens C, Venet A, Guillet JG, Bourgault-Villada I. Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J Virol (1999) 73(5):4447-51.
134. Evans TG, Fitzgerald T, Gibbons DC, Keefer MC, Soucier H. Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. The AIDS Vaccine Evaluation Group. Clin Exp Immunol (1998) 111(2):243-50.
135. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 191(5):654-65. doi:10.1086/428404.
136. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 194(12):1661-71. doi:10.1086/508748.
137. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 372(9653):1881-93. doi:10.1016/S0140-6736(08)61591-3.
138. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 372(9653):1894-905. doi:10.1016/S0140-6736(08)61592-5.